Amgen shares are closing near attractive entry levels for a medium term horizon. Investors could regard the decline over the past weeks as a buying opportunity. Investors have an opportunity to buy the stock and target the $ 192.
The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Historically, the company has been releasing figures that are above expectations.
According to Thomson-Reuters' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
The company's "enterprise value to sales" ratio is among the highest in the world.